Lihua Min
Center for Excellence in Molecular Cell Science(CN)University of Chinese Academy of Sciences(CN)
Publications by Year
Research Areas
Liver physiology and pathology, PI3K/AKT/mTOR signaling in cancer, Sirtuins and Resveratrol in Medicine, TGF-β signaling in diseases, Cancer Mechanisms and Therapy
Most-Cited Works
- → Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin(2012)249 cited
- → A Pharmacogenomic Landscape in Human Liver Cancers(2019)213 cited
- → Mitogen-activated protein kinases in hepatocellular carcinoma development(2010)180 cited
- → Sorafenib inhibits transforming growth factor β1-Mediated Epithelial-Mesenchymal Transition and apoptosis in mouse hepatocytes(2011)97 cited
- → Nitric oxide suppresses transforming growth factor-β1–induced epithelial-to-mesenchymal transition and apoptosis in mouse hepatocytes #(2009)45 cited
- → Mediator MED23 regulates inflammatory responses and liver fibrosis(2019)17 cited
- → Design, Synthesis, and Biological Evaluation of Novel Orally Available Covalent CDK12/13 Dual Inhibitors for the Treatment of Tumors(2025)10 cited
- → Synthesis and structure-activity optimization of azepane-containing derivatives as PTPN2/PTPN1 inhibitors(2024)7 cited
- → Erratum: Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin(2013)4 cited
- → Targeting MED23 inhibits hepatocellular carcinoma development by suppressing compensatory proliferation and facilitating ROS-mediated cell death(2025)1 cited